ZINC ARSENITE

inorganic, salt 

ARSENENOUS ACID, ZINC SALT; ARSENIOUS ACID, (HAsO2), ZINC SALT; ZINC ARSENITE, Zn(AsO2)2; ZINC METAARSENITE; ZINC META-ARSENITE; ZMA; UN 1712; As2O4Zn

Emergency Overview 

Color:  colorless to white 

Change in color: Not available

Physical Form: powder

Health Hazards:  harmful if swallowed, respiratory tract irritation, skin irritation, eye irritation, cancer hazard (in humans) 

Short Term:  same as effects reported in short term ingestion, irritation, difficulty breathing 

Long Term:  same as effects reported in short term ingestion, cancer 

Short Term:  irritation, allergic reactions, absorption may occur 

Long Term:  same as effects reported in short term exposure, skin disorders, cancer 

Short Term:  irritation, sensitivity to light 

Long Term:  same as effects reported in short term exposure 

Short Term:  weakness, nausea, vomiting, diarrhea, dizziness, headache, chest pain, stomach pain, changes in body temperature, skin disorders, white lines on the fingernails, changes in blood pressure, pain in extremities, blood disorders, liver damage, kidney damage, nerve damage 

Long Term:  same as effects reported in short term exposure, nosebleed, bleeding gums, cancer 

This product may be regulated, have exposure limits or other information identified as the following: Arsenic compounds, n.o.s., Zinc compounds, Arsenic, inorganic compounds.

If adverse effects occur, remove to uncontaminated area. Give artificial respiration if not breathing. Get immediate medical attention. 

Wash skin with soap and water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention, if needed. Thoroughly clean and dry contaminated clothing and shoes before reuse. 

Flush eyes with plenty of water for at least 15 minutes. Then get immediate medical attention. 

Contact local poison control center or physician immediately. Never make an unconscious person vomit or drink fluids. When vomiting occurs, keep head lower than hips to help prevent aspiration. If person is unconscious, turn head to side. Get medical attention immediately. 

For ingestion, consider gastric lavage. 

dimercaprol, intramuscular; penicillamine, oral. calcium disodium edetate/dextrose, intravenous; calcium disodium edetate/procaine, intramuscular. 

See Section 9 for Flammability Properties 

Negligible fire hazard. 

regular dry chemical, carbon dioxide, water, regular foam Large fires: Use regular foam or flood with fine water spray. 

Move container from fire area if it can be done without risk. Use extinguishing agents appropriate for surrounding fire. Avoid inhalation of material or combustion by-products. Stay upwind and keep out of low areas. 

Subject to California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65). Keep out of water supplies and sewers. 

Do not touch spilled material. Stop leak if possible without personal risk. Small spills: Absorb with sand or other non-combustible material. Collect with absorbent into suitable container. Small dry spills: Collect spilled material in appropriate container for disposal. Move containers away from spill to a safe area. Large spills: Dike for later disposal. Keep unnecessary people away, isolate hazard area and deny entry. 

Use methods to minimize dust. 

Store and handle in accordance with all current regulations and standards. Keep separated from incompatible substances. 

Component Exposure Limits 

Biological limit value 

Provide local exhaust or process enclosure ventilation system. Ensure compliance with applicable exposure limits. 

Eyes/Face Wear splash resistant safety goggles with a faceshield. Provide an emergency eye wash fountain and quick drench shower in the immediate work area. 

Wear appropriate chemical resistant clothing. 

Wear appropriate chemical resistant gloves. OSHA REGULATED SUBSTANCES: U.S. OSHA 29 CFR 1910.1018. 

The following respirators and maximum use concentrations are drawn from NIOSH and/or OSHA. OSHA Standard: Respirator selection should comply with 29 CFR 1910.134, 29 CFR 1910.1018, and the final rule published in the Federal Register on August 24, 2006. NIOSH Recommendations: At any detectable concentration - Any self-contained breathing apparatus that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode. Any supplied-air respirator with a full facepiece that is operated in a pressure-demand or other positive-pressure mode in combination with an auxiliary self-contained breathing apparatus operated in pressure-demand or other positive-pressure mode. Escape - Any air-purifying full-facepiece respirator (gas mask) with a chin-style, front-mounted or back-mounted acid gas canister having an N100, R100, or P100 filter. Any appropriate escape-type, self-contained breathing apparatus. 

acids 

Stable at normal temperatures and pressure. 

Avoid heat, flames, sparks and other sources of ignition. Avoid generating dust. Keep out of water supplies and sewers. 

No data available. 

arsenic, oxides of zinc 

Thermal decomposition products: arsenic, zinc oxide.

Will not polymerize. 

Component Analysis - LD50/LC50 

Component Carcinogenicity

An increased incidence of skin and lung cancer has been associated with inorganic arsenic through medical treatment, contaminated drinking water, or occupational exposure Cancers at other sites have also been reported, but a clear association has not been confirmed. 

diabetes, heart or cardiovascular disorders, immune system disorders or allergies, kidney disorders, liver disorders, nervous system disorders, skin disorders and allergies, 

INORGANIC ARSENIC COMPOUNDS: Inorganic arsenic compounds may cause irritation of the respiratory tract with cough, foamy sputum, pain in the chest, dyspnea, and possibly pulmonary edema There may be cyanosis of the face, giddiness, restlessness, lassitude, headache, extreme general weakness, an initial rise, then fall in temperature, hypotension, pain in the limbs, and leukocytosis Delayed gastrointestinal symptoms may include nausea, vomiting, colic and diarrhea Acute, severe systemic intoxication by inhalation is unlikely, but if sufficient amounts are absorbed, other effects as described in acute ingestion are possible One case of a single prolonged exposure to an arsenical weed spray resulted in megaloblastic anemia.

INORGANIC ARSENIC COMPOUNDS: Repeated exposure to inorganic arsenic compounds may cause weakness, persistent headache, anorexia, weight loss, fatigue, pallor, malaise, low grade fever, salivation, and gastrointestinal disturbances with nausea, occasional vomiting, a sense of heaviness in the stomach, colic and diarrhea alternating with constipation Effects on mucous membranes may result in conjunctivitis with a sensation of irritation and lacrimation, a catarrhal state of the nose, larynx, and respiratory passages, coryza, hoarseness, mild tracheobronchitis, and stomatitis Perforation of the nasal septum may occur Many forms of skin lesions are possible including pigmentation (melanosis), erythema, eczema, keratosis of palms and soles, localized subcutaneous edema, especially of the eyelids, scaling and desquamation, and brittle nails, white bands on the nails (Mees lines), alopecia and vitiligo Peripheral neuritis may develop, initially of the hands and feet, which is usually sensory with paresthesia, hypesthesia, pain, burning, and tenderness In very severe cases, motor paralysis and muscle atrophy may occur with foot and wrist drop Effects on the liver, kidney, and hematopoietic and cardiovascular systems may occur, but are more common with chronic ingestion Inorganic arsenic compounds have been shown to be lung and skin carcinogens in humans The latency time between onset of exposure and the appearance of cancer is usually between 15 and 30 years.

ZINC ARSENITE See information on inorganic arsenic compounds.

INORGANIC ARSENIC COMPOUNDS: Inorganic arsenic compounds may be irritating, especially with prolonged contact Some absorption may occur, mainly through damaged skin or when applied in a lipid vehicle Some arsenic compounds are sensitizers and sensitization dermatitis may occur in previously exposed persons ZINC SALTS: Soluble zinc salts are astringent and corrosive and may be easily absorbed through the skin.

INORGANIC ARSENIC COMPOUNDS: Exposure to airborne inorganic arsenic compounds may cause burning and itching with two types of dermatitis due to local irritation or sensitization: An eczematous type with erythema, swelling and papules or vesicles and a follicular type with erythema and follicular swelling or pustules The dermatitis is usually localized on the most heavily exposed areas such as the face, back of the neck, forearms, wrists and hands Chronic dermal lesions may follow this type of initial reaction, but usually only after many years of exposure Hyperkeratosis, warts and melanosis of the skin are conspicuous signs These chronic skin lesions, particularly the hyperkeratosis, may develop into precancerous and cancerous lesions ZINC SALTS: No data available.

ZINC ARSENITE See information on inorganic arsenic compounds and zinc salts.

INORGANIC ARSENIC COMPOUNDS Inorganic arsenic compounds may cause irritation and conjunctivitis with itching, burning, lacrimation, photophobia and sometimes hyperemia and chemosis.

INORGANIC ARSENIC COMPOUNDS Repeated or prolonged contact with inorganic arsenic compounds may cause conjunctivitis as in acute exposure.

ZINC ARSENITE See information on inorganic arsenic compounds.

INORGANIC ARSENIC COMPOUNDS: Large doses of arsenic or inorganic arsenic compounds may cause systemic poisoning with symptoms usually appearing one-half to four hours after ingestion Symptoms may include burning and pain in the chest, esophagus, stomach and bowel, throat constriction, dysphagia, weakness, and a sweetish metallic taste Violent gastroenteritis may occur with vomiting, copious watery or bloody diarrhea containing shreds of mucus, and dehydration with intense thirst and muscular cramps There may be a garlic odor to the breath, vomit and feces Vertigo, frontal headache, fever, sweating, restlessness, confusion, delirium and even mania may occur With less than lethal doses, some symptoms may develop without prominent gastrointestinal signs Later symptoms may include cold, clammy skin, cyanosis, rapid, feeble pulse, hypotension, shock, cardiac disturbances, including ventricular fibrillation, and general paralysis Death within 1-48 hours is usually due to circulatory failure; coma and convulsions may occur terminally Death delayed 3-14 days is usually due to dehydration, electrolyte imbalance and gradual hypotension Liver and kidney degenerative changes may be present If the acute phase is survived delayed sequelae may include: a variety of skin lesions, alopecia, Mees lines, edema of the face and eyelids, and conjunctivitis; neuropathy with sensory and motor involvement; encephalopathy; liver damage with multiple profile abnormalities, jaundice, and hepatomegaly; renal failure with hematuria, albuminuria, glucosuria, and oliguria or anuria; and anemia and leukopenia, especially neutropenia Weakness and diarrhea may persist for weeks Inorganic arsenic crosses the placental barrier A case of ingestion of arsenic trioxide in the 30th week of pregnancy resulted in maternal toxicity; premature delivery and neonatal death followed ZINC SALTS: Small doses may cause nausea and vomiting In addition to these symptoms, large doses may cause fever, stomach cramps, diarrhea, and fatal collapse due to serious damage to the buccal and gastroenteric mucous membranes.

INORGANIC ARSENIC COMPOUNDS: Repeated ingestion of small amounts of arsenic or inorganic arsenic compounds may cause effects as described in chronic inhalation Other reported symptoms include metallic taste, thirst, garlic odor to the breath and sweat, anxiety, hot flushes, ataxia, mental confusion, edema of the ankles and lower eyelids, nose bleeds and bleeding gums Liver effects may include jaundice, hepatomegaly, cirrhosis, ascites, non-cirrhotic portal hypertension, and fatty infiltration and central necrosis The kidneys may be severely damaged and there may be oliguria, proteinuria, hematuria, and casts Hematologic effects may include anemia, leukopenia, especially neutropenia, thrombocytopenia without severe bleeding, disturbed erythropoiesis, and disturbed or depressed myelopoiesis Aplastic anemia with subsequent fatal myelogenous leukemia has been reported Reported cardiovascular effects include severe cardiac peripheral edema and left-sided heart failure and gangrene of the extremities due to peripheral vascular changes An increased incidence of chromosomal aberrations has been observed in persons treated with arsenical compounds Cancer in humans is associated with chronic ingestion of arsenic ZINC SALTS: Continued administration of small doses may cause digestive disorders and constipation.

ZINC ARSENITE See information on inorganic arsenic compounds and zinc salts.

Component Analysis - Aquatic Toxicity 

Dispose in accordance with all applicable regulations. Hazardous Waste Number(s): D004. Dispose of in accordance with U.S. EPA 40 CFR 262 for concentrations at or above the Regulatory level. Regulatory level- 5.0 mg/L. 

Component Waste Numbers 

Component Marine Pollutants (IMDG) 

SARA Section 311/312 (40 CFR 370 Subparts B and C) 

The following statement(s) are provided under the California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): 

REACH List of Substances Subject to Restriction (Annex XVII) - Reg. (EU) No. 1907/2006 

The listed component(s) of this material have been checked for country-specific published classifications according to the Globally Harmonized System of Classification and Labeling (GHS). The results of the queries are displayed below. Please see the individual country listings, as additional interpretations or reference information may be available. For a reference list of H- or P-statements, please visit ChemADVISOR’s website at http://www.chemadvisor.com/product-resources/26-pure-substance-and-mixture-databases/247-ghs-hazard-and-physical-statements 

Australia GHS Classifications 

Australia GHS Labeling Information 

European Union GHS Classifications 

European Union GHS Labeling Information 

Indonesia GHS Classifications 

Japan GHS Classifications 

Korea GHS Classifications 

Korea GHS Labeling Information 

New Zealand GHS Classifications 

South Africa GHS Classifications 

Taiwan GHS Classifications 

Taiwan GHS Labeling Information 

No classification assigned. 

ACGIH - American Conference of Governmental Industrial Hygienists; ADR - European Road Transport; AU - Australia; BOD - Biochemical Oxygen Demand; C - Celsius; CA - Canada; CAS - Chemical Abstracts Service; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CN - China; CPR - Controlled Products Regulations; DFG - Deutsche Forschungsgemeinschaft; DOT - Department of Transportation; DSL - Domestic Substances List; EEC - European Economic Community; EINECS - European Inventory of Existing Commercial Chemical Substances; EPA - Environmental Protection Agency; EU - European Union; F - Fahrenheit; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; ICAO - International Civil Aviation Organization; IDL - Ingredient Disclosure List; IDLH - Immediately Dangerous to Life and Health; IMDG - International Maritime Dangerous Goods; JP - Japan; Kow - Octanol/water partition coefficient; KR - Korea; LEL - Lower Explosive Limit; LOLI - List Of LIsts™ - ChemADVISOR’s Regulatory Database; MAK - Maximum Concentration Value in the Workplace; MEL - Maximum Exposure Limits; NFPA - National Fire Protection Agency; NIOSH - National Institute for Occupational Safety and Health; NJTSR - New Jersey Trade Secret Registry; NTP - National Toxicology Program; NZ - New Zealand; OSHA - Occupational Safety and Health Administration; PH - Philippines; RCRA - Resource Conservation and Recovery Act; RID - European Rail Transport; RTECS - Registry of Toxic Effects of Chemical Substances®; SARA - Superfund Amendments and Reauthorization Act; STEL - Short-term Exposure Limit; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act; TWA - Time Weighted Average; UEL - Upper Explosive Limit; US - United States 

Reasonable care has been taken in the preparation of this information; however, the manufacturer makes no warranty whatsoever including the warranty of merchantability, expressed or implied, with respect to this information. The manufacturer makes no representations and assumes no liability for any direct, incidental, consequential, or other such damages resulting from its use or misuse. 

Supplier gives no warranty whatsoever, including the warranties of merchantability or of fitness for a particular purpose. Any product purchased is sold on the assumption the purchaser shall determine the quality and suitability of the product. Supplier expressly disclaims any and all liability for incidental, consequential or any other damages arising out of the use or misuse of this product. No information provided shall be deemed to be a recommendation to use any product in conflict with any existing patent rights. THIS SDS IS TO BE UTILIZED SOLELY AS A REFERENCE DOCUMENT AND IT IS NOT TO BE USED TO SATISFY THE DISTRIBUTION REQUIREMENTS OF OSHA'S HAZARD COMMUNICATION STANDARD (HCS) NOR CANADA'S CONTROLLED PRODUCT REGULATION (CPR). Read the Safety Data Sheet before handling product. Use of any information contained herein is provided at the reader's own risk and thus independent judgment by trained professionals must be utilized at all times. 

Copyright 1984-2016 ChemADVISOR, Inc "RTECS®" is a United States trademark owned and licensed under authority of the U.S. Government, by and through Accelrys/Biovia. Portions ©Copyright 2016, U.S. Government. All rights reserved